Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 20 April 1990:
Vol. 248. no. 4953, pp. 358 - 361
DOI: 10.1126/science.2183354
Prev | Table of Contents | Next

Articles

Science, Vol 248, Issue 4953, 358-361
Copyright © 1990 by American Association for the Advancement of Science

articles

Rational design of peptide-based HIV proteinase inhibitors

NA Roberts, JA Martin, D Kinchington, AV Broadhurst, JC Craig, IB Duncan, SA Galpin, BK Handa, J Kay, A Krohn, and al. et

Roche Products Ltd., Hertfordshire, United Kingdom.

A series of peptide derivatives based on the transition-state mimetic concept has been designed that inhibit the proteinase from the human immunodeficiency virus (HIV). The more active compounds inhibit both HIV-1 and HIV-2 proteinases in the nanomolar range with little effect at 10 micromolar against the structurally related human aspartic proteinases. Proteolytic cleavage of the HIV-1 gag polyprotein (p55) to the viral structural protein p24 was inhibited in chronically infected CEM cells. Antiviral activity was observed in the nanomolar range (with one compound active below 10 nanomolar) in three different cell systems, as assessed by p24 antigen and syncytium formation. Cytotoxicity was not detected at 10 and 5 micromolar in C8166 and JM cells, respectively, indicating a high therapeutic index for this new class of HIV proteinase inhibitors.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals.
W. R. L. de Campos, D. Coopusamy, L. Morris, B. M. Mayosi, and M. Khati (2009)
Antimicrob. Agents Chemother. 53, 3056-3064
   Abstract »    Full Text »    PDF »
Importance of Protease Cleavage Sites within and Flanking Human Immunodeficiency Virus Type 1 Transframe Protein p6* for Spatiotemporal Regulation of Protease Activation.
C. Ludwig, A. Leiherer, and R. Wagner (2008)
J. Virol. 82, 4573-4584
   Abstract »    Full Text »    PDF »
HIV protease inhibitors and nuclear lamin processing: Getting the right bells and whistles.
S. G. Clarke (2007)
PNAS 104, 13857-13858
   Full Text »    PDF »
Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro against Plasmodium falciparum and In Vivo against Murine Malaria.
K. T. Andrews, D. P. Fairlie, P. K. Madala, J. Ray, D. M. Wyatt, P. M. Hilton, L. A. Melville, L. Beattie, D. L. Gardiner, R. C. Reid, et al. (2006)
Antimicrob. Agents Chemother. 50, 639-648
   Abstract »    Full Text »    PDF »
Human Immunodeficiency Virus Type 1 Protease Inhibitors Block Toll-Like Receptor 2 (TLR2)- and TLR4-Induced NF-{kappa}B Activation.
O. Equils, A. Shapiro, Z. Madak, C. Liu, and D. Lu (2004)
Antimicrob. Agents Chemother. 48, 3905-3911
   Abstract »    Full Text »    PDF »
HIV Drug Resistance.
F. Clavel and A. J. Hance (2004)
N. Engl. J. Med. 350, 1023-1035
   Full Text »    PDF »
The Eukaryotic Translation Initiation Factor 4GI Is Cleaved by Different Retroviral Proteases.
E. Alvarez, L. Menendez-Arias, and L. Carrasco (2003)
J. Virol. 77, 12392-12400
   Abstract »    Full Text »    PDF »
Specific Phosphorylation of Exogenous Protein and Peptide Substrates by the Human Cytomegalovirus UL97 Protein Kinase. IMPORTANCE OF THE P+5 POSITION.
M.-C. Baek, P. M. Krosky, Z. He, and D. M. Coen (2002)
J. Biol. Chem. 277, 29593-29599
   Abstract »    Full Text »    PDF »
Anti-TAR Polyamide Nucleotide Analog Conjugated with a Membrane-Permeating Peptide Inhibits Human Immunodeficiency Virus Type 1 Production.
N. Kaushik, A. Basu, P. Palumbo, R. L. Myers, and V. N. Pandey (2002)
J. Virol. 76, 3881-3891
   Abstract »    Full Text »    PDF »
Interference between D30N and L90M in Selection and Development of Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1.
W. Sugiura, Z. Matsuda, Y. Yokomaku, K. Hertogs, B. Larder, T. Oishi, A. Okano, T. Shiino, M. Tatsumi, M. Matsuda, et al. (2002)
Antimicrob. Agents Chemother. 46, 708-715
   Abstract »    Full Text »    PDF »
The Late-Domain-Containing Protein p6 Is the Predominant Phosphoprotein of Human Immunodeficiency Virus Type 1 Particles.
B. Muller, T. Patschinsky, and H.-G. Krausslich (2002)
J. Virol. 76, 1015-1024
   Abstract »    Full Text »    PDF »
Molecular Basis for the Relative Substrate Specificity of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Proteases.
Z. Q. Beck, Y.-C. Lin, and J. H. Elder (2001)
J. Virol. 75, 9458-9469
   Abstract »    Full Text »    PDF »
Vif Is Largely Absent from Human Immunodeficiency Virus Type 1 Mature Virions and Associates Mainly with Viral Particles Containing Unprocessed Gag.
P. Sova, D. J. Volsky, L. Wang, and W. Chao (2001)
J. Virol. 75, 5504-5517
   Abstract »    Full Text »
Extended nucleocapsid protein is cleaved from the Gag-Pol precursor of human immunodeficiency virus type 1.
N. Chen, A. Morag, N. Almog, I. Blumenzweig, O. Dreazin, and M. Kotler (2001)
J. Gen. Virol. 82, 581-590
   Abstract »    Full Text »
BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents.
B. S. Robinson, K. A. Riccardi, Y.-f. Gong, Q. Guo, D. A. Stock, W. S. Blair, B. J. Terry, C. A. Deminie, F. Djang, R. J. Colonno, et al. (2000)
Antimicrob. Agents Chemother. 44, 2093-2099
   Abstract »    Full Text »
Identification of a Key Target Sequence To Block Human Immunodeficiency Virus Type 1 Replication within the gag-pol Transframe Domain.
S. Sei, Q.-e. Yang, D. O'Neill, K. Yoshimura, K. Nagashima, and H. Mitsuya (2000)
J. Virol. 74, 4621-4633
   Abstract »    Full Text »
Comparison of Human Immunodeficiency Virus Type 1 Pr55Gag and Pr160Gag-Pol Processing Intermediates That Accumulate in Primary and Transformed Cells Treated with Peptidic and Nonpeptidic Protease Inhibitors.
R. R. Speck, C. Flexner, C.-J. Tian, and X.-F. Yu (2000)
Antimicrob. Agents Chemother. 44, 1397-1403
   Abstract »    Full Text »
Assembly and Processing of Human Immunodeficiency Virus Gag Mutants Containing a Partial Replacement of the Matrix Domain by the Viral Protease Domain.
C.-T. Wang, Y.-C. Chou, and C.-C. Chiang (2000)
J. Virol. 74, 3418-3422
   Abstract »    Full Text »
High-Level Resistance to 3'-Azido-3'-Deoxythimidine due to a Deletion in the Reverse Transcriptase Gene of Human Immunodeficiency Virus Type 1.
T. Imamichi, T. Sinha, H. Imamichi, Y.-M. Zhang, J. A. Metcalf, J. Falloon, and H. C. Lane (2000)
J. Virol. 74, 1023-1028
   Abstract »    Full Text »
Resistance against Syncytium-Inducing Human Immunodeficiency Virus Type 1 (HIV-1) in Selected CD4+ T Cells from an HIV-1-Infected Nonprogressor: Evidence of a Novel Pathway of Resistance Mediated by a Soluble Factor(s) That Acts after Virus Entry.
K. Saha, D. J. Volsky, and E. Matczak (1999)
J. Virol. 73, 7891-7898
   Abstract »    Full Text »
Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug Interaction.
G. N. Kumar, J. Dykstra, E. M. Roberts, V. K. Jayanti, D. Hickman, J. Uchic, Y. Yao, B. Surber, S. Thomas, and G. R. Granneman (1999)
Drug Metab. Dispos. 27, 902-908
   Abstract »    Full Text »
Competitive Inhibition of Human Immunodeficiency Virus Type-1 Protease by the Gag-Pol Transframe Protein.
C. Paulus, S. Hellebrand, U. Tessmer, H. Wolf, H.-G. Krausslich, and R. Wagner (1999)
J. Biol. Chem. 274, 21539-21543
   Abstract »    Full Text »    PDF »
Processing, Activity, and Inhibition of Recombinant Cyprosin, an Aspartic Proteinase from Cardoon (Cynara cardunculus).
P. C. White, M. C. Cordeiro, D. Arnold, P. E. Brodelius, and J. Kay (1999)
J. Biol. Chem. 274, 16685-16693
   Abstract »    Full Text »    PDF »
Stabilization from Autoproteolysis and Kinetic Characterization of the Human T-cell Leukemia Virus Type 1 Proteinase.
J. M. Louis, S. Oroszlan, and J. Tozser (1999)
J. Biol. Chem. 274, 6660-6666
   Abstract »    Full Text »    PDF »
Actin Associates with the Nucleocapsid Domain of the Human Immunodeficiency Virus Gag Polyprotein.
T. Wilk, B. Gowen, and S. D. Fuller (1999)
J. Virol. 73, 1931-1940
   Abstract »    Full Text »
In Vitro Metabolism of the HIV-1 Protease Inhibitor ABT-378: Species Comparison and Metabolite Identification.
G. N. Kumar, V. Jayanti, R. D. Lee, D. N. Whittern, J. Uchic, S. Thomas, P. Johnson, B. Grabowski, H. Sham, D. Betebenner, et al. (1999)
Drug Metab. Dispos. 27, 86-91
   Abstract »    Full Text »
Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif.
M. J. Potash, G. Bentsman, T. Muir, C. Krachmarov, P. Sova, and D. J. Volsky (1998)
PNAS 95, 13865-13868
   Abstract »    Full Text »    PDF »
Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors.
D. Boden and M. Markowitz (1998)
Antimicrob. Agents Chemother. 42, 2775-2783
   Full Text »
Cell Cycle Arrest by Vpr in HIV-1 Virions and Insensitivity to Antiretroviral Agents.
B. Poon, K. Grovit-Ferbas, S. A. Stewart, and I. S. Chen (1998)
Science 281, 266-269
   Abstract »    Full Text »
N-Terminal Extension of Human Immunodeficiency Virus Capsid Protein Converts the In Vitro Assembly Phenotype from Tubular to Spherical Particles.
I. Gross, H. Hohenberg, C. Huckhagel, and H.-G. Krausslich (1998)
J. Virol. 72, 4798-4810
   Abstract »    Full Text »    PDF »
Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors.
P. J. Ala, R. J. DeLoskey, E. E. Huston, P. K. Jadhav, P. Y. S. Lam, C. J. Eyermann, C. N. Hodge, M. C. Schadt, F. A. Lewandowski, P. C. Weber, et al. (1998)
J. Biol. Chem. 273, 12325-12331
   Abstract »    Full Text »    PDF »
HIV-Protease Inhibitors.
C. Flexner (1998)
N. Engl. J. Med. 338, 1281-1293
   Full Text »    PDF »
Single-Dose Pharmacokinetics of Indinavir and the Effect of Food.
K. C. Yeh, P. J. Deutsch, H. Haddix, M. Hesney, V. Hoagland, W. D. Ju, S. J. Justice, B. Osborne, A. T. Sterrett, J. A. Stone, et al. (1998)
Antimicrob. Agents Chemother. 42, 332-338
   Abstract »    Full Text »
Endogenous Production of beta -Chemokines by CD4+, but Not CD8+, T-Cell Clones Correlates with the Clinical State of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals and May Be Responsible for Blocking Infection with NonSyncytium-Inducing HIV-1 In Vitro.
K. Saha, G. Bentsman, L. Chess, and D. J. Volsky (1998)
J. Virol. 72, 876-881
   Abstract »    Full Text »    PDF »
Design of potent and selective human cathepsin K inhibitors that span the active site.
S. K. Thompson, S. M. Halbert, M. J. Bossard, T. A. Tomaszek, M. A. Levy, B. Zhao, W. W. Smith, S. S. Abdel-Meguid, C. A. Janson, K. J. D'Alessio, et al. (1997)
PNAS 94, 14249-14254
   Abstract »    Full Text »    PDF »
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy.
R. M. Gulick, J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, et al. (1997)
N. Engl. J. Med. 337, 734-739
   Abstract »    Full Text »    PDF »
Human Immunodeficiency Virus Type 1 Protease Inhibitors.
C. K. McDonald and D. R. Kuritzkes (1997)
Arch Intern Med 157, 951-959
   Abstract »    PDF »
HIV-1 Protease Inhibitors: A Review for Clinicians.
S. G. Deeks, M. Smith, M. Holodniy, and J. O. Kahn (1997)
JAMA 277, 145-153
   Abstract »    PDF »
A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection.
M. Markowitz, M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. L. Marca, J. M. Leonard, et al. (1995)
N. Engl. J. Med. 333, 1534-1540
   Abstract »    Full Text »    PDF »
Therapy for Human Immunodeficiency Virus Infection.
M. S. Hirsch and R. T. D'Aquila (1993)
N. Engl. J. Med. 328, 1686-1695
   Full Text »
Present status and future prospects for HIV therapies.
M. Johnston and D. Hoth (1993)
Science 260, 1286-1293
   Abstract »    PDF »
Structure-Based Strategies for Drug Design and Discovery.
I. D. Kuntz (1992)
Science 257, 1078-1082
   Abstract »    PDF »
Antiretroviral Chemotherapy of Human Immunodeficiency Virus Infections Other Than With Azidothymidine.
M. K. Sachs (1992)
Arch Intern Med 152, 485-501
   Abstract »    PDF »
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease.
J Erickson, D. Neidhart, J VanDrie, D. Kempf, X. Wang, D. Norbeck, J. Plattner, J. Rittenhouse, M Turon, N Wideburg, et al. (1990)
Science 249, 527-533
   Abstract »    PDF »
Interactions of a Novel Inhibitor from an Extremophilic Bacillus sp. with HIV-1 Protease. IMPLICATIONS FOR THE MECHANISM OF INACTIVATION.
C. Dash and M. Rao (2001)
J. Biol. Chem. 276, 2487-2493
   Abstract »    Full Text »    PDF »
Isolation of peptide aptamers that inhibit intracellular processes.
J. H. Blum, S. L. Dove, A. Hochschild, and J. J. Mekalanos (2000)
PNAS 97, 2241-2246
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)